NCT04750928View on ClinicalTrials.gov

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Neurofibromatosis 1
Interventions
DRUG

Abemaciclib

Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH